Skip to content

Released Aug 11, 2025, after the close

10-Q filed Aug 11, 2025, 42 days after period end · 0001708599-25-000089

Q2 2025 · 10-Q
Revenue$130.00K+154.9% vs Q2 2024no prior Q1 2025 on file
Net Income-$6.45MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.66N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$5,565,000N/M
Operating Cash Flowderived-$3,750,000N/M
Free Cash Flowderived-$3,796,000N/M
Margins · derived
Operating margin-4280.8%+3299.6 pt vs Q2 2024
Net margin-4960.0%

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$130.00K$51.00K$7.00K$12.00K
Net Income-$6.45M$5.20M$808.00K-$2.62M
EPS Diluted-$0.66$0.51$0.11-$0.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Serina Therapeutics, Inc. · CIK 1708599 · Engraved from SEC EDGAR